| Literature DB >> 33991462 |
Huapeng Lu1,2, Qinling Yang1, Lili Yang1, Kai Qu1, Boyan Tian1, Qigui Xiao1, Xia Xin3, Yi Lv1,2, Xuemei Zheng3.
Abstract
BACKGROUND: Both midline catheters (MCs) and peripherally inserted central catheters (PICCs) can cause venous thromboembolism (VTE), but the prevalence associated with each is controversial.Entities:
Keywords: complication; intravenous therapy; midline catheter; peripherally inserted central catheter; systematic review; venous thromboembolism
Mesh:
Year: 2021 PMID: 33991462 PMCID: PMC8994959 DOI: 10.1002/nop2.935
Source DB: PubMed Journal: Nurs Open ISSN: 2054-1058
FIGURE 1Summary of the literature identification and selection process
Characteristics of included studies with a comparison group
| Study | Study design | Study location | Study period | Population | Study indicators | MC group | PICC group | |||
|---|---|---|---|---|---|---|---|---|---|---|
| VTE | Total | VTE | Total | |||||||
| (Seo et al., | RC | New York, US | Nov. 2017 to Jul. 2018 | ≥18 years | Demographics, catheter‐related adverse events (local events, catheter dislodgment, infiltration, occlusion, VTE, extravasation, line‐associated infection), risk factors for complications, data on catheter gauge, the use of ultrasound during placement, the service placing the line, anticoagulation and/or antiplatelet therapy, in situ time of the midline, site of placement, total number of medications infused, medication type, duration of therapy, vesicant properties. | 2 | 82 | 0 | 50 | |
| (Kaatz et al., | RC | Michigan, US | NR | non‐surgical cancer patients | Demographics, device characteristics, catheter use, medical conditions, medications, 30 days after device placement rates of VTE | 3 | 160 | 83 | 2113 | |
| (Bahl et al., | RC | Michigan, US | Jul. 2016 to Aug. 2017 | ≥18 years | Demographics, date and time of line placement, type of line, diameter of line, number of line lumens, catheter‐to‐vein ratio, vein accessed, line laterality, number of attempts, indication for line, upper extremity venous duplex ultrasonography, VTE | 130 | 1094 | 102 | 1483 | |
| (Zohourian et al., | RC | Florida, US | NR | NR | Age, lumen size, major surgery, previous VTE, body mass index, catheter infection, thrombophilia, critically illness, inferior vena cava filters, pacemaker, implantable cardioverter defibrillator, anticoagulation, catheter insertion site | 6 | 123 | 91 | 1560 | |
| (Sharma et al., | RC | Missouri, US | NR | NR | DVT, location of DVT, type of catheter | 3 | 122 | 50 | 1365 | |
| (Tso et al., | RC | San Francisco, US | Feb. 25, 2008, to Oct. 31, 2014 | adult and paediatric | Age, sex, diagnosis, presence of aura, total cumulative dose (dihydroergotamine) or maximum dose reached (lidocaine), type of IV line used, number of days with a PICC or MC, DVT, PE | 8 | 110 | 13 | 205 | |
| (Xu et al., | RC | Pennsylvania, US | Jan‐May 2015 | 19–98 years | Demographics, comorbidity score, length of stay, insertion location, line duration, complications | 2 | 200 | 2 | 206 | |
| (Lisova et al., | RC | Prague, Czech Republic | During 2013 | 23–90 years | Complications (infection, VTE, occlusion, displacement) | 12 | 162 | 6 | 167 | |
| (Caparas & Hu, | RCT | New York, US | NR | ≥ one dose and ≥6 days vancomycin | Demographics, administration of other antibiotics, average number of days on vancomycin, dwell time, complications | 0 | 30 | 0 | 28 | |
| (Sharp et al., | RC | Adelaide, Australia | 2004 to 2010 | 18–47 years | Demographics, comorbid conditions, inpatients/outpatients, severity of exacerbation, lung function, adverse events (catheter‐related bloodstream infection, DVT, occlusion, pain, infiltration, bleeding, phlebitis, catheter leakage, dislodgement), and whether the VAD was removed unexpectedly | 3 | 231 | 0 | 97 | |
| (Benali et al., | RCT | Montreal, Canada | NR | ≤18 years and weighed ≥3 kg | Demographics, dwell time, catheter complications (DVT, infection) | 5 | 69 | 0 | 84 | |
| (Moureau et al., | RC | California, US | Apr. 1999 to Sep. 2000 | 1–101 years | Age, sex, type of VAD, principal diagnosis, complications by event and device type, underlying causes and outcomes of DVT dysfunction | 136 | 5423 | 411 | 25707 | |
Abbreviations: NR, not reported; RC, retrospective cohort study; RCT, randomized controlled trial.
Quality of included studies
| Study | reporting | External validity | Internal validity ‐ bias | Internal validity ‐ confounding | Power | Total |
|---|---|---|---|---|---|---|
| (Seo et al., | 9 | 3 | 5 | 2 | 2 | Good (21) |
| (Kaatz et al., | 6 | 1 | 3 | 0 | 1 | Poor (11) |
| (Bahl et al., | 9 | 2 | 3 | 3 | 3 | Good (20) |
| (Zohourian et al., | 6 | 2 | 4 | 2 | 3 | Fair (17) |
| (Sharma et al., | 3 | 1 | 2 | 1 | 2 | Poor (9) |
| (Tso et al., | 7 | 2 | 3 | 4 | 2 | Fair (18) |
| (Xu et al., | 10 | 3 | 4 | 4 | 2 | Good (23) |
| (Lisova et al., | 5 | 1 | 3 | 2 | 2 | Poor (13) |
| (Caparas & Hu, | 9 | 3 | 4 | 5 | 2 | Good (23) |
| (Sharp et al., | 9 | 3 | 4 | 3 | 3 | Good (22) |
| (Benali et al., | 4 | 1 | 4 | 4 | 1 | Poor (14) |
| (Moureau et al., | 7 | 2 | 4 | 3 | 3 | Fair (19) |
FIGURE 2Pooled results for VTE between MCs and PICCs
FIGURE 3Funnel plots of publication bias for VTE